FOXP1 and Huntington disease: Unfortunately, phase II clinical trials with MP‐10 (NCT01806896, NCT02197130, NCT02342548) in patients with advanced symptoms of HD failed to meet the prespecified endpoints of the trial, despite the promising data in HD mouse models.[33, 34]This result, however, cannot be extrapolated to FOXP1 syndrome for multiple reasons.